
Yoshitsugu Aoki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6720728/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1360-1372.	2.9	22
2	Editorial: Challenges and Opportunities for Neuromuscular Disease Modelling Using Urine-derived Stem Cells. Frontiers in Physiology, 2022, 13, 848220.	1.3	0
3	Brain Dp140 alters glutamatergic transmission and social behaviour in the mdx52 mouse model of Duchenne muscular dystrophy. Progress in Neurobiology, 2022, 216, 102288.	2.8	12
4	Size-tunable PEG-grafted copolymers as a polymeric nanoruler for passive targeting muscle tissues. Journal of Controlled Release, 2022, 347, 607-614.	4.8	6
5	Development of outcome measures according to dystrophic phenotypes in canine X-linked muscular dystrophy in Japan. Experimental Animals, 2021, 70, 419-430.	0.7	2
6	Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides. Nucleic Acid Therapeutics, 2021, 31, 172-181.	2.0	9
7	Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient <i>mdx</i> mice. Human Molecular Genetics, 2021, 30, 1006-1019.	1.4	28
8	Highly sensitive screening of antisense sequences for different types of DMD mutations in patients' urine-derived cells. Journal of the Neurological Sciences, 2021, 423, 117337.	0.3	3
9	eSkip-Finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping. Nucleic Acids Research, 2021, 49, W193-W198.	6.5	13
10	Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases. Journal of Neuromuscular Diseases, 2021, 8, 869-884.	1.1	19
11	A symptomatic male carrier of Duchenne muscular dystrophy with Klinefelter's syndrome mimicking Becker muscular dystrophy. Neuromuscular Disorders, 2021, 31, 666-672.	0.3	0
12	Fine Tuning of Phosphorothioate Inclusion in 2′-O-Methyl Oligonucleotides Contributes to Specific Cell Targeting for Splice-Switching Modulation. Frontiers in Physiology, 2021, 12, 689179.	1.3	0
13	Lipidomic Analyses Reveal Specific Alterations of Phosphatidylcholine in Dystrophic Mdx Muscle. Frontiers in Physiology, 2021, 12, 698166.	1.3	5
14	Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy. Molecular and Cellular Proteomics, 2020, 19, 2047-2068.	2.5	25
15	The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice. BMC Medicine, 2020, 18, 343.	2.3	12
16	Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells. Journal of Visualized Experiments, 2020, , .	0.2	4
17	Novel EGFP reporter cell and mouse models for sensitive imaging and quantification of exon skipping. Scientific Reports, 2020, 10, 10110.	1.6	3
18	Severe cardiac involvement with preserved truncated dystrophin expression in Becker muscular dystrophy by +1G>A DMD splice-site mutation: a case report. Journal of Human Genetics, 2020, 65, 903-909.	1.1	3

Yoshitsugu Aoki

#	Article	IF	CITATIONS
19	Dystrobrevin alpha gene is a direct target of the vitamin D receptor in muscle. Journal of Molecular Endocrinology, 2020, 64, 195-208.	1.1	5
20	Age-Dependent Echocardiographic and Pathologic Findings in a Rat Model with Duchenne Muscular Dystrophy Generated by CRISPR/Cas9 Genome Editing. International Heart Journal, 2020, 61, 1279-1284.	0.5	8
21	Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides. Journal of Visualized Experiments, 2020, , .	0.2	0
22	Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion. Methods in Molecular Biology, 2020, 2176, 185-208.	0.4	1
23	Autoimmune response and its longâ€ŧerm consequences after exonâ€skipping therapy in a Duchenne muscular dystrophy mouse model. Journal of Pathology, 2019, 249, 271-273.	2.1	2
24	Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine, 2019, 45, 630-645.	2.7	61
25	Supramolecular Assembly of Aminoethylene‣ipopeptide PMO Conjugates into RNA Spliceâ€&witching Nanomicelles. Advanced Functional Materials, 2019, 29, 1906432.	7.8	14
26	Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches. Journal of Personalized Medicine, 2019, 9, 1.	1.1	84
27	Exons 45–55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene. Molecular Therapy, 2019, 27, 2005-2017.	3.7	35
28	Potential Therapies Using Myogenic Stem Cells Combined with Bio-Engineering Approaches for Treatment of Muscular Dystrophies. Cells, 2019, 8, 1066.	1.8	14
29	Amelioration of intracellular Ca2+ regulation by exon-45 skipping in Duchenne muscular dystrophy-induced pluripotent stem cell-derived cardiomyocytes. Biochemical and Biophysical Research Communications, 2019, 520, 179-185.	1.0	14
30	Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride. Scientific Reports, 2019, 9, 3807.	1.6	18
31	Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle. Molecular Therapy - Nucleic Acids, 2019, 14, 520-535.	2.3	22
32	Application of Urine-Derived Stem Cells to Cellular Modeling in Neuromuscular and Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2019, 12, 297.	1.4	19
33	Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates. Molecular Therapy, 2019, 27, 76-86.	3.7	24
34	Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Science Translational Medicine, 2018, 10, .	5.8	111
35	Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Methods in Molecular Biology, 2018, 1687, 123-141.	0.4	13
36	Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs. PLoS ONE, 2018, 13, e0208415.	1.1	6

Үознітѕиси Аокі

#	Article	IF	CITATIONS
37	Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition. Biochemical and Biophysical Research Communications, 2018, 505, 51-59.	1.0	24
38	In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice. Methods in Molecular Biology, 2018, 1828, 275-292.	0.4	4
39	In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs. Methods in Molecular Biology, 2018, 1828, 365-379.	0.4	3
40	Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy. Methods in Molecular Biology, 2018, 1828, 553-564.	0.4	3
41	In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient. Methods in Molecular Biology, 2018, 1828, 151-163.	0.4	2
42	Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. PLoS ONE, 2018, 13, e0197084.	1.1	22
43	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2017, 140, 887-897.	3.7	126
44	Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy. Methods in Molecular Biology, 2017, 1565, 201-213.	0.4	19
45	Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4213-4218.	3.3	94
46	Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Molecular Therapy, 2017, 25, 2561-2572.	3.7	63
47	Comparative high resolution proteomic analysis of dystrophic mouse models reveals a core dystrophic proteome and the impact of aging. Neuromuscular Disorders, 2017, 27, S167-S168.	0.3	0
48	Dystrophin-deficient cardiomyocyte derived from Duchenne Muscular Dystrophy specific induced pluripotent stem cells carrying the deletion of exon 46-55 in DMD gene. Journal of the Neurological Sciences, 2017, 381, 859.	0.3	0
49	Solid-Phase Synthesis of Difficult Purine-Rich PNAs through Selective Hmb Incorporation: Application to the Total Synthesis of Cell Penetrating Peptide-PNAs. Frontiers in Chemistry, 2017, 5, 81.	1.8	15
50	Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Design, Development and Therapy, 2016, Volume 10, 2745-2758.	2.0	54
51	Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot. International Journal of Molecular Sciences, 2016, 17, 1722.	1.8	35
52	741. Development of LNA Gapmer Oligonucleotide Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion. Molecular Therapy, 2016, 24, S292.	3.7	0
53	Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy. Journal of Visualized Experiments, 2016, , .	0.2	16
54	Deletion of exons 3â^'9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. Journal of Human Genetics, 2016, 61, 663-667.	1.1	45

Yoshitsugu Aoki

#	Article	IF	CITATIONS
55	Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy. American Journal of Pathology, 2016, 186, 1302-1312.	1.9	27
56	Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. American Journal of Translational Research (discontinued), 2016, 8, 2471-89.	0.0	57
57	Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?. Neurodegenerative Disease Management, 2015, 5, 93-95.	1.2	2
58	Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. Nano Letters, 2015, 15, 4364-4373.	4.5	80
59	Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice. Molecular Therapy - Nucleic Acids, 2015, 4, e225.	2.3	67
60	Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environmental Health and Preventive Medicine, 2014, 19, 452-458.	1.4	86
61	G.P.85. Neuromuscular Disorders, 2014, 24, 820.	0.3	1
62	Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucleic Acids Research, 2013, 41, 9500-9513.	6.5	83
63	Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy. BioMed Research International, 2013, 2013, 1-8.	0.9	45
64	Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Human Molecular Genetics, 2013, 22, 4914-4928.	1.4	59
65	Identification of Disease Specific Pathways Using in Vivo SILAC Proteomics in Dystrophin Deficient mdx Mouse. Molecular and Cellular Proteomics, 2013, 12, 1061-1073.	2.5	88
66	Mutation Types and Aging Differently Affect Revertant Fiber Expansion in Dystrophic Mdx and Mdx52 Mice. PLoS ONE, 2013, 8, e69194.	1.1	26
67	Oligonucleotide-Based Therapy for FTD/ALS Caused by theC9orf72Repeat Expansion: A Perspective. Journal of Nucleic Acids, 2013, 2013, 1-11.	0.8	8
68	Bodywide skipping of exons 45–55 in dystrophic <i>mdx52</i> mice by systemic antisense delivery. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13763-13768.	3.3	139
69	Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs. Nucleic Acid Therapeutics, 2012, 22, 306-315.	2.0	69
70	New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy. Journal of Advanced Computational Intelligence and Intelligent Informatics, 2012, 16, 521-526.	0.5	0
71	Synthesis of 2′- <i>O</i> -[2-(<i>N</i> -Methylcarbamoyl)ethyl]ribonucleosides Using Oxa-Michael Reaction and Chemical and Biological Properties of Oligonucleotide Derivatives Incorporating These Modified Ribonucleosides. Journal of Organic Chemistry, 2011, 76, 3042-3053.	1.7	32
72	Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy. , 2011, , .		0

Yoshitsugu Аокі

#	Article	IF	CITATIONS
73	Identification of Muscle-Specific MicroRNAs in Serum of Muscular Dystrophy Animal Models: Promising Novel Blood-Based Markers for Muscular Dystrophy. PLoS ONE, 2011, 6, e18388.	1.1	178
74	Synthesis and biological properties of 2'-O-modified oligoribonucleotide derivatives. , 2011, , .		0
75	Antisense PMO Found in Dystrophic Dog Model Was Effective in Cells from Exon 7-Deleted DMD Patient. PLoS ONE, 2010, 5, e12239.	1.1	56
76	In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52–Deficient mdx Mouse. Molecular Therapy, 2010, 18, 1995-2005.	3.7	118
77	P3.04 Skipping of exons 6 and 8 of the DMD gene has been achieved in myogenic cells from an exon-7 deleted DMD patient: direct application of antisense sequences found in study with canine muscular dystrophy. Neuromuscular Disorders, 2010, 20, 641-642.	0.3	Ο
78	Relationship between diffusion tensor imaging and brain morphology in patients with myotonic dystrophy. Neuroscience Letters, 2006, 407, 234-239.	1.0	50
79	Development of Therapeutic RNA Manipulation for Muscular Dystrophy. Frontiers in Genome Editing, 0, 4, .	2.7	5